Overview

Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study is to assess the efficacy and safety of 0.1% and 0.03% Tacrolimus ointment for 12 months in adults with moderate to severe atopic dermatitis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Tacrolimus
Criteria
Inclusion Criteria:

- Patient may be male or female of any ethnic group

- Patient without restricted legal competence, and suffers from moderate to severe
atopic dermatitis (Rajka/Langeland score of at least 4.5)

- Patient known to be responsive to topical steroids

- Patient is capable of understanding the purposes and risks of the trial and has given
written Informed Consent

- Female patients of childbearing potential must agree to maintain adequate birth
control practice during the trial period and during the first four weeks after the end
of the study

- Patient meets the following criteria:

- Topical corticosteroids

- Systemic corticosteroids (for the treatment of AD only)

- Systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate)

- Other investigational drugs

- Light Treatments (UVA, UVB)

- Patient has not taken and agrees not to take for the complete study period any
medication or therapy prohibited by the protocol

Exclusion Criteria:

- Patient has a genetic epidermal barrier defect such as Netherton's syndrome or
generalised erythroderma

- Patient is pregnant or breast-feeding

- Patient has a skin infection on the affected (and to be treated) area

- Patient has a known hypersensitivity to macrolides in general, to tacrolimus or any
excipient of the ointment

- Patient is simultaneously participating in any other drug trial or less than 28 days
have passed between the end of the previous trial and this one

- Any form of substance abuse (including drug or alcohol abuse),psychiatric disorder or
condition which, in the opinion of the investigator, may invalidate the communication
with the investigator

- Patient is known to be HIV positive